IRVINE, Calif.--(BUSINESS WIRE)--CardiAQ Valve Technologies, Inc (www.cardiaq.com) announced today that it has appointed Jack Lips as Clinical Specialist Manager and Steven Marmon as Clinical Trial Manager. In these positions, they are individually responsible for differing aspects of overseeing the current Compassionate Feasibility Study, as well as initiating and managing the definitive multinational CE Mark clinical trial for the purpose of seeking marketing approval in Europe of the Company’s proprietary Trans-Femoral (TF) and Trans-Apical (TA) Systems for Transcatheter Mitral Valve Implantation (TMVI).
“The start of our definitive clinical trial for CE Marking in early 2015 will be a very significant milestone for CardiAQ in the process of clinically validating our two TMVI Systems,” said Rob Michiels, CEO of CardiAQ. “I am personally thrilled that Steven and Jack have again elected to join me in the realization of yet another frontier in medicine.”
“We are incredibly excited that Jack and Steven have joined our team, and I am confident that they will play a key role in sustaining CardiAQ as a clear leader in Transcatheter Mitral Valve Implantation,” said Brent Ratz, Co-Founder, President and COO of CardiAQ. “Together, they were instrumental in the multinational expansion of the CoreValve TAVR technology, and we look forward to having them apply their forty years of collective clinical and medical device experience to help bring CardiAQ’s TMVI technology to patients in need.”
Prior to joining CardiAQ, Mr. Lips most recently held similar responsibilities at CoreValve (Medtronic), one of the pioneer organizations in Transcatheter Aortic Valve Replacement. He also served in clinical management roles at St Jude Medical, Novoste and InterVentional Technologies. Prior to joining the medical device industry, Mr. Lips served in a variety of clinical and supervisory positions at the catheterization laboratory of the Medical Centre De Klokkenberg in Breda, The Netherlands. He is fluent in several languages and holds a nursing certificate from Nursing School St Ignatius-De Borg in Breda, The Netherlands.
Prior to joining CardiAQ, Mr. Marmon most recently held similar responsibilities at CoreValve (Medtronic), one of the pioneer organizations in Transcatheter Aortic Valve Replacement. He also served in clinical, sales, and marketing management roles at St Jude/Daig and InterVentional Technologies. Prior to joining the medical device industry, Mr. Marmon served in a variety of clinical and managerial positions at the catheterization laboratory of the East Tennessee Baptist Hospital in Knoxville, Tenn. He maintains RCIS, ACLS and EMT credentialing and holds a B.A, in Business Administration from National University.
Privately held CardiAQ, headquartered in Irvine, Calif., has developed a proprietary Transcatheter Mitral Valve (TMV) Implant that can be delivered through multiple delivery systems, including both Trans-femoral and Trans-apical. Through its unique anchoring mechanism that engages and utilizes the patient’s native mitral valve anatomy, physicians will be able to accurately and securely implant a new mitral valve within a beating heart, thus avoiding open-heart surgery. The CardiAQ procedures are designed to be performed in a cardiac catheterization laboratory or hybrid operating room. Ultimately, the procedure will result in less trauma to the patient and substantial potential cost-savings to the healthcare system.
Caution: The CardiAQ™ Valve Technologies System for Transcatheter Mitral Valve Implantation is in the early phases of development. It will not be available in the USA for clinical trials until further notice and is NOT available for sale.